Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

128P - Stereotactic ablative radiotherapy in locally-advanced non-small cell lung cancer patients: Little palliation or big cure? Sub-analysis of START-NEW-ERA phase II trial


31 Mar 2023


Poster Display session


Fabio Arcidiacono


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


F. Arcidiacono1, M. Casale2, E. Maranzano2, M. Italiani2, S. Fabiani2, C. Zannori2, B. Enrico2, A. Guida2, F. Trippa2, P. Anselmo3

Author affiliations

  • 1 Terni/IT
  • 2 "S.Maria" Hospital, Terni/IT
  • 3 "S.Maria" Hospital, 05100 - Terni/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 128P


Early analysis1 of a single arm phase II trial assessed local control (LC) and safety of stereotactic ablative radiotherapy (SAbR) unresectable locally advanced non-small cell lung cancer (LA-NSCLC) patients unfit for concurrent chemo-radiotherapy (ChT-RT). Here we report clinical outcomes of LA-NSCLC patients submitted to exclusive SAbR.


Between December 31, 2015 and June 30, 2022 71 LA-NSCLC patients were enrolled. 40 (56%) and 31 (44%) received neoadjuvant ChT+SAbR and exclusive SAbR, respectively. The tumor volume included primary tumor (T) and any regionally positive node/s (N). The co-primary study endpoints were LC and safety.


The median age was 80 years (range, 45–88). Twenty (64%) and eleven (36%) patients had PS 0–1 and 2, respectively. Histology was adenocarcinoma (ADC) and squamous cell carcinoma (SCC) in 71% and 29%, respectively. 27 (87%) patients had ultra-central tumor. Median prescribed dose was 45 Gy (range, 35–55) and 40 Gy (35–45) in 5 daily fractions to T and N, respectively. After a median follow-up of 27 months (range, 6–92), 9 (29%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7–34). The median LR-free survival (FS) was not reached (95% CI, 28 to not reached). The 1-, 2- and 4- year LR-FS rates were 81 ± 7%, 66 ± 9% and 66 ± 9%, respectively. At last follow-up, 23 (74%) patients were alive. Median overall survival (OS) was not reached. The 1, 2, and 4-year OS rates were 97 ± 3%, 74 ± 8% and 70 ± 9%, respectively. Eight (26%) patients developed distant progression (dP). The median dP-FS was not reached (95% CI, 26 to not reached). The 1, 2, and 4-year dP-FS rates were 82 ± 7%, 72 ± 9% and 66 ± 10%, respectively.


LA-NSCLC patients treated with exclusive SAbR had optimal local control and promising overall survival with excellent treatment compliance and absence of ≥G3 toxicity. Our preliminary prospective clinical outcomes provide an attraction to evaluate this approach in patients unfit to ChT, to obtain a “big” cure beyond “little” palliation.

1 Int J Radiat Oncol Biol Phys. 2022 Oct 24;S0360–3016(22)03459–9. doi: 10.1016/j.ijrobp.2022.10.025.

Clinical trial identification


Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.